Literature DB >> 12242334

The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Jay N Lozier1, Amalia Dutra, Evgenia Pak, Nan Zhou, Zhili Zheng, Timothy C Nichols, Dwight A Bellinger, Marjorie Read, Richard A Morgan.   

Abstract

In the Chapel Hill colony of factor VIII-deficient dogs, abnormal sequence (ch8, for canine hemophilia 8, GenBank no. ) follows exons 1-22 in the factor VIII transcript in place of exons 23-26. The canine hemophilia 8 locus (ch8) sequence was found in a 140-kb normal dog genomic DNA bacterial artificial chromosome (BAC) clone that was completely outside the factor VIII gene, but not in BAC clones containing the factor VIII gene. The BAC clone that contained ch8 also contained a homologue of F8A (factor 8 associated) sequence, which participates in a common inversion that causes severe hemophilia A in humans. Fluorescence in situ hybridization analysis indicated that exons 1-26 normally proceed sequentially from telomere to centromere at Xq28, and ch8 is telomeric to the factor VIII gene. The appearance of an "upstream" genomic sequence element (ch8) at the end of the aberrant factor VIII transcript suggested that an inversion of genomic DNA replaced factor VIII exons 22-26 with ch8. The F8A sequence appeared also in overlapping normal BAC clones containing factor VIII sequence. We hypothesized that homologous recombination between copies of canine F8A inside and outside the factor VIII gene had occurred, as in human hemophilia A. High-resolution fluorescent in situ hybridization on hemophilia A dog DNA revealed a pattern consistent with this inversion mechanism. We also identified a HindIII restriction fragment length polymorphism of F8A fragments that distinguished hemophilia A, carrier, and normal dogs' DNA. The Chapel Hill hemophilia A dog colony therefore replicates the factor VIII gene inversion commonly seen in humans with severe hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242334      PMCID: PMC130574          DOI: 10.1073/pnas.192219599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.

Authors:  K M Brinkhous; U Hedner; J B Garris; V Diness; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Expression and linkage of genes for X-linked hemophilias A and B in the dog.

Authors:  K M Brinkhous; P D Davis; J B Graham; W J Dodds
Journal:  Blood       Date:  1973-04       Impact factor: 22.113

3.  Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.

Authors:  Christine Hough; Seiki Kamisue; Cherie Cameron; Colleen Notley; Shawn Tinlin; Alan Giles; David Lillicrap
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

4.  A set of canine interrepeat sequence PCR markers for high-throughput genotyping.

Authors:  M Das; H Sakul; J Kong; G M Acland; J Pelletier
Journal:  Physiol Genomics       Date:  2000-11-09       Impact factor: 3.107

5.  Isolation of a 40-kDa Huntingtin-associated protein.

Authors:  M F Peters; C A Ross
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

6.  The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A.

Authors:  T C Nichols; D A Bellinger; R L Reddick; S V Smith; G G Koch; K Davis; J Sigman; K M Brinkhous; T R Griggs; M S Read
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

7.  A canine model of hemophilic (factor VIII:C deficiency) bleeding.

Authors:  A R Giles; S Tinlin; R Greenwood
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

8.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Canine hemophilia B resulting from a point mutation with unusual consequences.

Authors:  J P Evans; K M Brinkhous; G D Brayer; H M Reisner; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions.

Authors:  J B GRAHAM; J A BUCKWALTER
Journal:  J Exp Med       Date:  1949-08-01       Impact factor: 14.307

View more
  49 in total

1.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Authors:  Jonathan D Finn; Margareth C Ozelo; Denise E Sabatino; Helen W G Franck; Elizabeth P Merricks; Julie M Crudele; Shangzhen Zhou; Haig H Kazazian; David Lillicrap; Timothy C Nichols; Valder R Arruda
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

Review 2.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 3.  Man's best friend becomes biology's best in show: genome analyses in the domestic dog.

Authors:  Heidi G Parker; Abigail L Shearin; Elaine A Ostrander
Journal:  Annu Rev Genet       Date:  2010       Impact factor: 16.830

4.  Gene therapy for hemophilia: the clot thickens.

Authors:  Katherine A High
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

5.  From caveman companion to medical innovator: genomic insights into the origin and evolution of domestic dogs.

Authors:  Heidi G Parker; Samuel F Gilbert
Journal:  Adv Genomics Genet       Date:  2015-06-12

6.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

8.  Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

Authors:  Denise E Sabatino; Christian Furlan Freguia; Raffaella Toso; Andrey Santos; Elizabeth P Merricks; Haig H Kazazian; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

9.  Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.

Authors:  C D Porada; C Sanada; C R Long; J A Wood; J Desai; N Frederick; L Millsap; C Bormann; S L Menges; C Hanna; G Flores-Foxworth; T Shin; M E Westhusin; W Liu; H Glimp; E D Zanjani; J N Lozier; V Pliska; G Stranzinger; H Joerg; D C Kraemer; G Almeida-Porada
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

10.  The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.

Authors:  Katherine A High
Journal:  Trans Am Clin Climatol Assoc       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.